SCHEMBL1884371

SCHEMBL1884371

COc1ccc(COn2c(=O)[nH]c3c(sc4ccc([N+](=O)[O-])cc43)c2=O)c(OC)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.51
▸ HTT P42858 5/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ TDP1 Q9NUW8 2/20 0.51
▸ LMNA P02545 1/20 0.51
▸ GLA P06280 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ CTSV O60911 1/20 0.41
▸ CTSL P07711 1/20 0.41
▸ MCL1 Q07820 1/20 0.39
▸ ALDH1A1 P00352 7/20 0.37
▸ KMT2A Q03164 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ GAA P10253 2/20 0.36
▸ POLB P06746 2/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ SNCA P37840 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1887745 0.85 ADRA1D (0.47) MAPTHTTSMN1; SMN2TDP1LMNA
SCHEMBL1893465 0.71 ERCC5 (0.60) MAPTHTTSMN1; SMN2TDP1LMNA
SCHEMBL1891707 0.70 PARP15 (0.46) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL1885584 0.69 ERCC5 (0.48) MAPTSMN1; SMN2TDP1ALDH1A1KMT2A
SCHEMBL1890470 0.69 RXFP1 (0.52) MAPTHTTLMNAALDH1A1KMT2A
SCHEMBL8168895 0.67 HDAC3 (0.55) MAPTHTTSMN1; SMN2CTSVCTSL
SCHEMBL1892321 0.64 CNR2 (0.38) MAPTHTTSMN1; SMN2TDP1LMNA
SCHEMBL17040252 0.63 SNCA (0.50) MAPTHTTSMN1; SMN2TDP1LMNA
SCHEMBL1181214 0.63 CTSV (0.86) MAPTHTTSMN1; SMN2LMNACTSV
SCHEMBL1615885 0.62 HTT (0.60) MAPTHTTSMN1; SMN2TDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947691-B2 Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof ATHERSYS, INC. (US) 2011-05-24 — — US disclosed
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof ATHERSYS, INC. (US) 2008-11-20 — — US disclosed
WO-2006014647-A2 CYCLIC N-HYDROXY IMIDES AS INHIBITORS OF FLAP ENDONUCLEASE AND USES THEREOF ATHERSYS, INC. (US) 2006-02-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof FEN1, UNG, POLH MAPT 4773/4885HTT 3629/4885SMN1; SMN2 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback